Skip to main content
Geneuro logo

Geneuro — Investor Relations & Filings

Ticker · GEM ISIN · CH0308403085 LEI · 213800FUJCKXO9LK3444 PA Professional, scientific and technical activities
Open in API
Filings indexed 221 across all filing types
Latest filing 2020-01-31 Capital/Financing Update
Country CH Switzerland
Listing PA GEM

About Geneuro

https://geneuro.ch/en/

Geneuro is a clinical-stage biopharmaceutical company developing treatments for neurological and autoimmune diseases. The company's approach focuses on neutralizing pathogenic proteins expressed by human endogenous retroviruses (HERVs), which are believed to be causal factors in the progression of certain diseases. Its primary areas of development include conditions such as multiple sclerosis (MS) and post-COVID syndrome (long-COVID). Geneuro's lead product candidate, temelimab, is a monoclonal antibody designed to target and neutralize a specific HERV envelope protein. This strategy aims to block the inflammatory and neurodegenerative processes associated with these diseases, representing a precision medicine approach to treatment.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Capital/Financing Update Classification · 1% confidence The document is a press release announcing a successful private placement of shares (capital raise) by GeNeuro. It details the number of shares issued, the subscription price, the use of proceeds, and the impact on share capital and voting rights. This falls squarely under the definition of a Capital/Financing Update (CAP), as it describes a specific fundraising activity and changes to the company's capital structure.
2020-01-31 English
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 1% confidence The document is a press release announcing a private placement of shares (capital increase) by GeNeuro. It details the amount raised (17.5 million euros), the number of shares issued, the purpose of the funds, and the impact on the company's capital structure. This falls under the category of capital and financing updates.
2020-01-31 French
Informations privilégiées / Information sur chiffre d’affaires annuel
Earnings Release Classification · 1% confidence The document is a press release from GeNeuro titled 'Position de trésorerie au 31 décembre 2019, retour sur 2019 et perspectives 2020'. It provides a summary of financial highlights (cash position), clinical trial updates, and future outlooks. It is an initial announcement of periodic financial status and business developments, which fits the definition of an Earnings Release (ER) as it provides key highlights of the company's performance for the period ending December 31, 2019. FY 2019
2020-01-30 French
Inside Information / Information on annual revenues
Earnings Release Classification · 1% confidence The document is a press release from GeNeuro titled 'Cash position at December 31, 2019, Business Update and Outlook for 2020'. It provides a summary of financial highlights (cash position), clinical trial updates, and future business outlook. It is not a full annual report (10-K) or a transcript of a call (CT), but rather a periodic update on company performance and business activities, which fits the definition of an Earnings Release (ER) or a general business update announcement. FY 2019
2020-01-30 English
Inside Information / Other news releases
Earnings Release Classification · 1% confidence The document is a press release titled 'GeNeuro Reports 2018 Full-Year Results and Provides Corporate Update'. It contains key financial highlights, a summary of the consolidated income statement, and business outlook information for the fiscal year ended December 31, 2018. While it provides financial data, it is structured as a press release (Earnings Release) rather than the full, formal 10-K or Annual Report document. It serves as the initial announcement of the annual financial results. FY 2018
2019-04-01 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 1% confidence The document is a press release from GeNeuro announcing its annual financial results for the fiscal year 2018. It includes key financial highlights, a summary of clinical developments, and a consolidated income statement. While it contains financial data, it is structured as an initial earnings announcement (press release) rather than the full, formal 10-K or Annual Report document. Therefore, it is classified as an Earnings Release. FY 2018
2019-04-01 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.